Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | POLQ | O75417 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18338261 | 0.91 | MEN1 (0.50) | TP53ALDH1A1HPGDNPSR1KDM4E | |
| SCHEMBL21975561 | 0.88 | MEN1 (0.53) | TP53ALDH1A1HPGDNPSR1KDM4E | |
| SCHEMBL18338188 | 0.88 | TP53 (0.65) | TP53MTNR1AMTNR1BALDH1A1NPSR1 | |
| SCHEMBL18350042 | 0.88 | TP53 (0.57) | TP53ALDH1A1NPSR1KDM4ELMNA | |
| SCHEMBL18338221 | 0.83 | TP53 (0.42) | TP53MTNR1AMTNR1BALDH1A1HPGD | |
| SCHEMBL18338219 | 0.83 | TP53 (0.42) | TP53MTNR1AMTNR1BALDH1A1HPGD | |
| SCHEMBL21900204 | 0.83 | TP53 (0.42) | TP53MTNR1AMTNR1BALDH1A1HPGD | |
| SCHEMBL18345112 | 0.80 | CCR2 (0.49) | MTNR1AMTNR1BALDH1A1HPGDKDM4E | |
| SCHEMBL18338268 | 0.80 | TP53 (0.67) | TP53NPSR1MEN1KMT2AMAPT | |
| SCHEMBL18338295 | 0.80 | LMNA (0.66) | TP53ALDH1A1KDM4EHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313846-B1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES | PROMEGA CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-3313846-B1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES | PROMEGA CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200063110-A1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
| US-20200063110-A1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
| EP-3313846-A1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES | Promega Corporation (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210294-A1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES | PROMEGA CORPORATION (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20160376568-A1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376568-A1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF | THOP1, TYMP, CREBBP | TP53 3720/4885MTNR1A 890/4885MTNR1B 771/4885 |
| US-20200063110-A1 | THIENOPYRROLE COMPOUNDS AND USES THEREOF | THOP1, TYMP, CREBBP | TP53 3720/4885MTNR1A 890/4885MTNR1B 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.